Read the poster preso title it tells you everything you need to know - they are going to be talking about the enhancement of pharmacokinetics of the drug due to adding IL2.
Here is the title...
Absract title: Administration of Low-Dose, Subcutaneous (SC) Interleukin-2 (IL-2) M
arkedly Enhances the Pharmacokinetic (PK) Profile of Azercabtagene Zapreleucel (azer-cel), an Allogeneic Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, without Compromising Safety and Early Evidence of Clinical Activity in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Have Relapsed after Prior CD19-Directed
CAR T-Cell Products.
Doesn't mean it's bad - it's just early stages - so don't get too excited - there will not be any new efficacy data etc.
How do I know? Cause the title tells you what they are presenting.
....... sincerely hoping and wishing for more cr's for patients sake........ us holders we all can live another day to find another investment gem....... but for cancer sufferers its life and death......... Go imu, Go you good thing
(20min delay)